| Vertex Pharmaceuticals develops and commercializes therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. Co.'s marketed products are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat people with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. Co. is co-developing CTX001, an investigational CRISPR/Cas9-based gene-editing therapy for sickle cell disease and transfusion-dependent beta thalassemia. We show 48 historical shares outstanding datapoints in our VRTX shares outstanding history coverage, used to compute VRTX market cap on those dates.|
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing VRTX market cap history over the course of time is important for investors
interested in comparing VRTX's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of VRTX versus a peer is one thing; comparing
VRTX market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like VRTX can fluctuate over the course of history.
With this page we aim to empower investors researching VRTX by allowing them to research the VRTX market cap history.